HIV-specific Immune Dysregulation and Atherosclerosis

Overview

Journal Curr HIV/AIDS Rep

Publisher Current Science

Specialty Infectious Diseases

Date 2012 May 29

PMID 22638983

Citations 17

Authors

Markella V Zanni

Steven K Grinspoon

Affiliations

Soon will be listed here.

Abstract

HIV + patients face a heightened risk of cardiovascular disease (CVD), which cannot be fully explained by traditional risk factors or antiretroviral therapy (ART)-related cardiotoxicity. Increasing evidence suggests a significant contribution of HIV-specific immune dysregulation to atherosclerosis. HIV-specific immune dysregulation may have the following atherogenic effects: 1) activation of endothelial and immune cells; 2) enhancement of the percentage of circulating atherogenic immune cell subsets; and 3) modification of lipid function. Efforts are underway to link immune dysregulation markers with validated CVD endpoints and to identify genetic predispositions for HIV-induced atherogenesis. Moreover, immune suppressants are under evaluation in HIV + patients to attempt modification of immune-mediated CVD risk. Taken together, these studies will enhance understanding of CVD risk stratification and reduction strategies in HIV.

Citing Articles

No accelerated progression of subclinical atherosclerosis with integrase strand transfer inhibitors compared to non-nucleoside reverse transcriptase inhibitors.

Garcia-Abellan J, Garcia J, Padilla S, Fernandez-Gonzalez M, Agullo V, Mascarell P J Antimicrob Chemother. 2024; 80(1):126-137.

PMID: 39450853 PMC: 11695909. DOI: 10.1093/jac/dkae383.

Effects of Opioid Withdrawal on Psychobiology in People Living with HIV.

Grant I, Krupitsky E, Vetrova M, Umlauf A, Heaton R, Hauger R Viruses. 2024; 16(1).

PMID: 38257791 PMC: 10818595. DOI: 10.3390/v16010092.

Association of CD4 + cell count and HIV viral load with risk of non-AIDS-defining cancers.

Ma Y, Zhang J, Yang X, Chen S, Weissman S, Olatosi B AIDS. 2023; 37(13):1949-1957.

PMID: 37382882 PMC: 10538428. DOI: 10.1097/QAD.0000000000003637.

Macrophage Polarity and Disease Control.

Kadomoto S, Izumi K, Mizokami A Int J Mol Sci. 2022; 23(1).

PMID: 35008577 PMC: 8745226. DOI: 10.3390/ijms23010144.

Predicting cardiovascular risk using a novel risk score in young and middle-age adults with HIV: associations with biomarkers and carotid atherosclerotic plaque.

Rodriguez V, Abbamonte J, Parrish M, Jones D, Weiss S, Pallikkuth S Int J STD AIDS. 2021; 33(2):144-155.

PMID: 34727754 PMC: 9356383. DOI: 10.1177/09564624211050335.

References

Hunt P, Brenchley J, Sinclair E, McCune J, Roland M, Page-Shafer K . Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008; 197(1):126-33. PMC: 3466592. DOI: 10.1086/524143. View

Takano Y, Shimokado K, Hata Y, Yoshida M . HIV envelope protein gp120-triggered CD4+ T-cell adhesion to vascular endothelium is regulated via CD4 and CXCR4 receptors. Biochim Biophys Acta. 2007; 1772(5):549-55. DOI: 10.1016/j.bbadis.2007.01.010. View

Duong M, Petit J, Martha B, Galland F, Piroth L, Walldner A . Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy. HIV Clin Trials. 2006; 7(2):41-7. DOI: 10.1310/7381-m1yd-rtv5-4ryt. View

Burdo T, Lo J, Abbara S, Wei J, DeLelys M, Preffer F . Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis. 2011; 204(8):1227-36. PMC: 3203384. DOI: 10.1093/infdis/jir520. View

Gupta S, Johnson R, Mather K, Clauss M, Rehman J, Saha C . Anti-inflammatory treatment with pentoxifylline improves HIV-related endothelial dysfunction: a pilot study. AIDS. 2010; 24(9):1377-80. PMC: 2891092. DOI: 10.1097/QAD.0b013e3283396024. View

Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P . Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003; 37(2):292-8. DOI: 10.1086/375844. View

Khovidhunkit W, Kim M, Memon R, Shigenaga J, Moser A, Feingold K . Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004; 45(7):1169-96. DOI: 10.1194/jlr.R300019-JLR200. View

Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, Chehimi J . Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients. AIDS. 2008; 23(3):369-75. PMC: 2745273. DOI: 10.1097/QAD.0b013e32831e9c76. View

Oliviero U, Bonadies G, Apuzzi V, Foggia M, Bosso G, Nappa S . Human immunodeficiency virus per se exerts atherogenic effects. Atherosclerosis. 2008; 204(2):586-9. DOI: 10.1016/j.atherosclerosis.2008.10.012. View

10.

Cota-Gomez A, Flores N, Cruz C, Casullo A, Aw T, Ichikawa H . The human immunodeficiency virus-1 Tat protein activates human umbilical vein endothelial cell E-selectin expression via an NF-kappa B-dependent mechanism. J Biol Chem. 2002; 277(17):14390-9. DOI: 10.1074/jbc.M108591200. View

11.

Baker J, Duprez D, Rapkin J, Hullsiek K, Quick H, Grimm R . Untreated HIV infection and large and small artery elasticity. J Acquir Immune Defic Syndr. 2009; 52(1):25-31. PMC: 2764552. DOI: 10.1097/qai.0b013e3181b02e6a. View

12.

Mujawar Z, Rose H, Morrow M, Pushkarsky T, Dubrovsky L, Mukhamedova N . Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol. 2006; 4(11):e365. PMC: 1629034. DOI: 10.1371/journal.pbio.0040365. View

13.

Stein J . Cardiovascular risks of antiretroviral therapy. N Engl J Med. 2007; 356(17):1773-5. DOI: 10.1056/NEJMe078037. View

14.

Papasavvas E, Azzoni L, Pistilli M, Hancock A, Reynolds G, Gallo C . Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following.... AIDS. 2008; 22(10):1153-61. PMC: 2726750. DOI: 10.1097/QAD.0b013e328303be2a. View

15.

Kuller L, Tracy R, Belloso W, De Wit S, Drummond F, Lane H . Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008; 5(10):e203. PMC: 2570418. DOI: 10.1371/journal.pmed.0050203. View

16.

Hsue P, Hunt P, Schnell A, Kalapus S, Hoh R, Ganz P . Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS. 2009; 23(9):1059-67. PMC: 2691772. DOI: 10.1097/QAD.0b013e32832b514b. View

17.

Rose H, Hoy J, Woolley I, Tchoua U, Bukrinsky M, Dart A . HIV infection and high density lipoprotein metabolism. Atherosclerosis. 2007; 199(1):79-86. PMC: 2518204. DOI: 10.1016/j.atherosclerosis.2007.10.018. View

18.

Park I, Wang J, Groopman J . HIV-1 Tat promotes monocyte chemoattractant protein-1 secretion followed by transmigration of monocytes. Blood. 2001; 97(2):352-8. DOI: 10.1182/blood.v97.2.352. View

19.

Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho J . Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS. 2009; 24(2):243-53. PMC: 3154841. DOI: 10.1097/QAD.0b013e328333ea9e. View

20.

Packard R, Lichtman A, Libby P . Innate and adaptive immunity in atherosclerosis. Semin Immunopathol. 2009; 31(1):5-22. PMC: 2823132. DOI: 10.1007/s00281-009-0153-8. View